Understanding Gout: An Overview

What is Gout?

Gout is a form of inflammatory arthritis that primarily affects the joints and surrounding tissues, particularly in the feet. The inflammation occurs due to the deposition of monosodium urate (MSU) crystals in affected areas. These crystals form as a result of hyperuricemia, which refers to elevated levels of uric acid in the blood.

Recent Developments in Gout Research

A recent collaboration involving 78 rheumatologists from 14 countries, under the 3e scientific initiative, reviewed existing clinical literature on gout. They compiled a series of recommendations focused on the diagnosis and treatment of this condition, which are summarized in this article.

Diagnosis of Gout

Diagnostic Techniques

The diagnosis of gout typically involves standard laboratory tests and X-ray imaging. However, recent advancements have shown that ultrasound and dual-energy CT scans may provide superior diagnostic capabilities. A key component of diagnosing gout is the identification of MSU crystals.

Associated Health Risks

Hyperuricemia is not only linked to gout but also increases the risk of developing diabetes, hypertension, and renal disease. Furthermore, individuals with gout face heightened risks for kidney disease, metabolic syndrome, coronary heart disease (CHD), and various cardiovascular conditions. Therefore, it is essential to screen for and diagnose potential complications related to these risks.

Treatment Options for Gout

Managing Inflammation

The committee evaluated various treatment strategies for inflammation. Low doses of colchicine (1.8 mg daily) have been found to be as effective and safer than high doses (4.8 mg). Additionally, glucocorticoids and non-steroidal anti-inflammatory drugs (NSAIDs) demonstrate comparable efficacy and safety.

Acute Gout Flare-Ups

For managing acute gout flare-ups, oral colchicine, NSAIDs administered directly into the joint, and intramuscular glucocorticoids have shown significant success.

Urate Lowering Therapy (ULT)

Urate Lowering Therapy (ULT) is recommended to decrease serum uric acid (SUA) levels. Both allopurinol and febuxostat are effective in achieving this goal. The guidelines stress the importance of initiating ULT at low doses and gradually increasing to more effective levels. In severe cases, uricase is recommended as the preferred treatment option after other therapies have been exhausted. Pegloticase is another effective medication but carries a higher risk of adverse events, and caution is advised when combining it with ULT.

Individualized Treatment Approaches

Each patient should be evaluated for the most appropriate treatment based on their flare-up frequency, disease duration, and the presence and size of tophi, which are protrusions in the skin, joints, and bones. Monitoring SUA levels is critical, as lower uric acid levels correlate with fewer flare-ups, the disappearance of crystal deposits, and the regression of tophi. The target SUA level for these beneficial outcomes is 0.36 mmol/L. Surgical intervention to remove tophi should be considered only in rare cases where issues like nerve compression, mechanical impingement, or infection arise.

Limitations and Considerations

The review’s limitations include the exclusive participation of rheumatologists in the decision-making process, potentially overlooking insights from other specialists, such as nephrologists and primary care physicians. This raises questions regarding the applicability of the recommendations for patients with coexisting conditions. Nonetheless, the guidelines provided represent a valuable multinational standard for gout treatment.

Reference

Sivera, F. et al. “Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative.” Annals of the Rheumatic Diseases: the EULAR Journal. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23868909. July 18, 2013.

Written by Julia Yusupova